Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Abbott India Ltd

₹ 27,775-0.45%
16 Jan 3:33 p.m. – close price
🔗abbott.co.in•BSE: 500488•NSE: ABBOTINDIA
Market Cap₹ 59,022 Cr.
Current Price₹ 27,775
High / Low₹ 37,000
Stock P/E39.2
Book Value₹ 1,888
Dividend Yield1.69 %
ROCE46.2 %
ROE35.7 %
Face Value₹ 10.0
Sales₹ 6,714 Cr.
OPM27.0 %
Mar Cap₹ 59,022 Cr.

ABOUT

Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1]It was established in 1944.[2]

KEY POINTS

Abbott GroupThe company is a part of Abbott Laboratories, USA which has a presence in 160 countries with leading medical devices, diagnostics, nutrition products, and branded generic medicines.[1]

Also present in buckets:
Red Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1671.8534.70401132.880.953124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1212.970.07
2.Divi's Lab.6239.7066.66165644.380.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7213.530.01
3.Torrent Pharma.4024.9562.86136222.570.81591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1413.260.33
4.Cipla1399.4020.77113039.590.941353.373.737589.447.6422.7228349.5725.405441.141351.173.3914.720.01
5.Lupin2174.2023.0799317.100.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0812.410.32
6.Dr Reddy's Labs1179.3017.0898427.950.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7412.950.16
7.Mankind Pharma2173.5551.3589725.230.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.968.890.55
8.Abbott India27775.0039.1759021.891.69415.2715.801757.157.6246.256714.3726.991508.95415.2714.7025.470.05
–Median: 149 Co.390.629.921763.550.1113.4911.71161.7610.5814.89591.7315.9345.2613.963.078.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
1,3791,3221,3431,4791,4941,4371,4391,5581,6331,6141,6051,7381,757
Expenses
1,0361,0101,0631,1241,1131,0491,1091,1671,1941,1781,1761,2931,255
Operating Profit
343312280355381388330391439436429446502
Other Income
34445056565681676072767370
Profit before tax
355335308390415422390437479488483493546
Tax %
25%26%25%26%25%26%26%25%25%26%24%26%24%
Net Profit
266247231290313311287328359361367366415
EPS in Rs
124.95116.16108.91136.59147.27146.35135.09154.36168.76169.78172.73172.18195.43

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
2,2762,2892,6142,9033,2983,6794,0934,3104,9195,3495,8496,4096,714
Expenses
2,0091,9772,2502,5052,7743,0743,3363,3883,8324,1434,3964,7144,902
Operating Profit
2673123653985256057579221,0881,2061,4531,6951,812
Other Income
494850571171131148177154248275291
Interest
0032429181916121120
Depreciation
22151416161760586670717274
Profit before tax
2953443984366216998039261,0801,2741,6181,8872,009
Net Profit
1982292552774014505936917999491,2011,4141,509
EPS in Rs
93.39107.75120.12130.19188.82211.93279.04325.04375.87446.80565.30665.64710.12
Dividend Payout %
25%29%29%31%29%31%90%85%73%73%73%71%–

Compounded Sales Growth

10 Years:11%
5 Years:9%
3 Years:9%
TTM:11%

Compounded Profit Growth

10 Years:20%
5 Years:19%
3 Years:21%
TTM:17%

Stock Price CAGR

10 Years:18%
5 Years:13%
3 Years:9%
1 Year:2%

Return on Equity

10 Years:30%
5 Years:32%
3 Years:34%
Last Year:36%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
21212121212121212121212121
Reserves
7679161,1741,3661,6721,9872,4102,5812,7993,1673,6784,2123,990
Borrowings
00000017515315211383197182
Other Liabilities
3514364216797239329401,0861,2531,2541,4111,4871,501
Total Liabilities
1,1391,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9175,694
Fixed Assets
989610811081105270251271237225336314
Gross Block
209.23215.65122.83139.69124.25164.35344.84340.62381.98366.93424.50552.63–
Accumulated Depreciation
110.98119.6114.3730.1042.8759.3975.0189.84110.98130.02199.56216.65–
CWIP
1436212114101823
Investments
0000000000000
Other Assets
1,0401,2741,5051,9502,3332,8353,2753,5893,9524,3154,9585,5635,357
Total Assets
1,1391,3741,6162,0662,4162,9413,5473,8404,2244,5565,1935,9175,694

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
1552152493071534996267279488931,2131,012
Cash from Investing Activity
-144-187-77-155-215-257-401-72-396-148-416182
Cash from Financing Activity
-42-58-80-90-102-143-217-582-637-639-745-925
Net Cash Flow
-31-309162-16599873-8610752269

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
182120222927282121222022
Inventory Days
101107911071121068311094807092
Days Payable
38545610192116104116122109114110
Cash Conversion Cycle
807454284917814-6-8-243
Working Capital Days
363032216322104-7-8-1497
ROCE %
39%40%38%34%41%37%35%35%38%41%46%46%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%74.99%
FIIs
0.20%0.19%0.19%0.19%0.18%0.18%0.18%0.17%0.17%0.16%0.16%0.16%0.19%
DIIs
8.38%8.61%8.77%8.83%8.73%8.91%8.81%9.00%9.01%8.91%9.18%9.11%9.00%
Public
16.42%16.20%16.05%16.01%16.09%15.92%16.01%15.86%15.85%15.94%15.67%15.74%15.83%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Abbott India Files Regulatory Certificate for Dematerialization Compliance

8th April 2026, 9:38 pm

Abbott India Opens Special Window for Physical Share Transfer and Dematerialisation

3rd April 2026, 9:38 pm

Abbott India Closes Trading Window from April 1, 2026

24th March 2026, 5:52 pm

Abbott India: Postal Ballot Results Confirm Approval for Mr. Vivek Mohan's Director Appointment

18th February 2026, 8:40 pm

Key Companies Publish Q3 FY26 Financial Results Amidst Regulatory Filings

13th February 2026, 9:12 pm

Published by Other Websites

External media mentions & references

Novo Nordisk Slashes Ozempic, Wegovy Prices in India to Fight Generics

5th April 2026, 3:57 pm

Emcure Slashes Obesity Drug Price 55%; Abbott, Generics Spark Pharma Price War

2nd April 2026, 10:10 pm

Novo Nordisk Fights India Price War With Clinical Data, Not Discounts

25th March 2026, 12:46 pm

Novo Nordisk India Braces for Generic Semaglutide Onslaught After Patent Expiry

23rd March 2026, 2:56 pm

Pharma Giants Launch Semaglutide Generics, ₹12K Cr Market Race Begins

23rd March 2026, 10:28 am

News Articles

Editorial & research coverage

Indian Pharma Market Surges Past ₹2.4 Lakh Crore, Strong Growth Seen
Indian Pharma Market Surges Past ₹2.4 Lakh Crore, Strong Growth Seen

7th January 2026, 6:45 pm

Pharma Stocks Surge on Brokerage Optimism, CRDMO Growth Outlook
Pharma Stocks Surge on Brokerage Optimism, CRDMO Growth Outlook

6th January 2026, 6:13 pm

India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?
India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?

15th December 2025, 5:27 pm

Abbott India: HUGE Investment Opportunity Unveiled! ICICI Securities Upgrades to BUY - See the New Target! 🚀
Abbott India: HUGE Investment Opportunity Unveiled! ICICI Securities Upgrades to BUY - See the New Target! 🚀

10th November 2025, 8:51 pm

Abbott India Reports 16% Profit Jump on Strong Revenue and Margins
Abbott India Reports 16% Profit Jump on Strong Revenue and Margins

6th November 2025, 2:19 pm

Documents

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

1d - Seeking shareholder approval to appoint Vivek Mohan as Non-Executive Director; e-voting Jan19–Feb17, results Feb19, 2026.

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

8 Jan - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025.

Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.

31 Dec - GST penalty Rs.2,40,46,491 for FY2018-19,2019-20,2021-22,2023-24; appeal planned; no material impact.

Announcement under Regulation 30 (LODR)-Change in Directorate

24 Dec - Ambati Venu resigns effective Dec 31, 2025; Vivek Mohan appointed additional director effective Jan 1, 2026.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Financial Year 2010

(from bse)

Credit Ratings

No credit ratings.

Concalls

Sep 2022

TranscriptRecording

Jun 2021

Transcript

Stock Analysis

Description

  1. Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. It was established in 1944.

Key Growth Triggers

  1. Abbott Group The company is a part of Abbott Laboratories, USA which has a presence in 160 countries with leading medical devices, diagnostics, nutrition products, and branded generic medicines.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Stock is trading at 15.1 times its book value
  2. The company has delivered a poor sales growth of 9.38% over past five years.
  3. Working capital days have increased from 24.9 days to 97.2 days

Key Dates To Watch

  1. August 1, 2025: Compounding order from RBI received.
  2. August 12, 2025: Board meeting to approve Q1 FY25 results.
  3. August 13, 2025: AGM held, dividend declared.
  4. August 18, 2025: Mr. Darshan Gada appointed Additional Director.
  5. September 15, 2025: Postal ballot e-voting commences for Mr. Gada.
  6. October 1, 2025: Trading window closed.
  7. October 14, 2025: Postal ballot e-voting ends for Mr. Gada.
  8. October 16, 2025: Results of shareholder vote for Mr. Gada to be declared.
  9. October 31, 2025: Mr. Munish Prashar's resignation effective.
  10. November 6, 2025: Board meeting for Q2 FY26/H1 FY26 results.
  11. November 24, 2025: Central Government approval for Mr. Kartik Rajendran's MD appointment.
  12. December 31, 2025: Mr. Ambati Venu resigns as Director.
  13. January 1, 2026: Trading window closed for Q4 FY26 (ending Dec 31, 2025).

Corporate Announcements

8th Apr 26
Impact Rating: 2
Abbott India filed a certificate with BSE confirming compliance with SEBI's dematerialization regulations for the quarter ended March 31, 2026, verified by KFin Technologies.
3rd Apr 26
Impact Rating: -
No description available.
24th Mar 26
Impact Rating: 6
Abbott India Limited has informed the stock exchanges about the closure of its trading window for designated persons and their relatives. This restriction begins on April 1, 2026.
18th Feb 26
Impact Rating: 1
Abbott India Limited announced the successful outcome of its postal ballot, with members overwhelmingly approving the appointment of Mr. Vivek Mohan as a Director effective January 1, 2026.
13th Feb 26
Impact Rating: -
No description available.